Androgen receptor regulation of local growth hormone in prostate cancer cells

M. Victoria Recouvreux, J. Boyang Wu, Allen C Gao, Svetlana Zonis, Vera Chesnokova, Neil Bhowmick, Leland W. Chung, Shlomo Melmed

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Prostate cancer (PCA) growth is mainly driven by androgen receptor (AR), and tumors that initially respond to androgen deprivation therapy (ADT) or AR inhibition usually relapse into a more aggressive, castration-resistant PCA (CRPC) stage. Circulating growth hormone (GH) has a permissive role in PCA development in animal models and in human PCA xenograft growth. As GH and GH receptor (GHR) are both expressed in PCA cells, we assessed whether prostatic GH production is linked to AR activity and whether GH contributes to the castration-resistant phenotype. Using online datasets, we found that GH is highly expressed in human CRPC. We observed increased GH expression in castration-resistant C4-2 compared with castration-sensitive LNCaP cells as well as in enzalutamide (MDV3100)-resistant (MDVR) C4-2B (C4-2B MDVR) cells compared with parental C4-2B.Wedescribe a negative regulation of locally producedGHby androgens/AR in PCA cells following treatment with AR agonists (R1881) and antagonists (enzalutamide, bicalutamide). We also show that GH enhances invasive behavior of CRPC 22Rv1 cells, as reflected by increased migration, invasion, and anchorage-independent growth, as well as expression of matrix metalloproteases. Moreover, GH induces expression of the AR splice variant 7, which correlates with antiandrogen resistance, and also induces insulinlike growth factor 1,which is implicated in PCA progression and ligandindependent AR activation. In contrast, blockade of GH action with the GHR antagonist pegvisomant reverses these effects both in vitro and in vivo. GH induction following ADT or AR inhibition may contribute to CRPC progression by bypassing androgen growth requirements.

Original languageEnglish (US)
Pages (from-to)2255-2268
Number of pages14
JournalEndocrinology
Volume158
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Androgen Receptors
Growth Hormone
Prostatic Neoplasms
Castration
Androgens
Passive Cutaneous Anaphylaxis
Growth
Androgen Receptor Antagonists
Metribolone
Somatotropin Receptors
Androgen Antagonists
Metalloproteases
Heterografts
Intercellular Signaling Peptides and Proteins
Animal Models
Phenotype
Recurrence
MDV 3100

ASJC Scopus subject areas

  • Endocrinology

Cite this

Recouvreux, M. V., Wu, J. B., Gao, A. C., Zonis, S., Chesnokova, V., Bhowmick, N., ... Melmed, S. (2017). Androgen receptor regulation of local growth hormone in prostate cancer cells. Endocrinology, 158(7), 2255-2268. https://doi.org/10.1210/en.2016-1939

Androgen receptor regulation of local growth hormone in prostate cancer cells. / Recouvreux, M. Victoria; Wu, J. Boyang; Gao, Allen C; Zonis, Svetlana; Chesnokova, Vera; Bhowmick, Neil; Chung, Leland W.; Melmed, Shlomo.

In: Endocrinology, Vol. 158, No. 7, 01.07.2017, p. 2255-2268.

Research output: Contribution to journalArticle

Recouvreux, MV, Wu, JB, Gao, AC, Zonis, S, Chesnokova, V, Bhowmick, N, Chung, LW & Melmed, S 2017, 'Androgen receptor regulation of local growth hormone in prostate cancer cells', Endocrinology, vol. 158, no. 7, pp. 2255-2268. https://doi.org/10.1210/en.2016-1939
Recouvreux MV, Wu JB, Gao AC, Zonis S, Chesnokova V, Bhowmick N et al. Androgen receptor regulation of local growth hormone in prostate cancer cells. Endocrinology. 2017 Jul 1;158(7):2255-2268. https://doi.org/10.1210/en.2016-1939
Recouvreux, M. Victoria ; Wu, J. Boyang ; Gao, Allen C ; Zonis, Svetlana ; Chesnokova, Vera ; Bhowmick, Neil ; Chung, Leland W. ; Melmed, Shlomo. / Androgen receptor regulation of local growth hormone in prostate cancer cells. In: Endocrinology. 2017 ; Vol. 158, No. 7. pp. 2255-2268.
@article{c2c2604ac8514b70a37ec3764c3c025d,
title = "Androgen receptor regulation of local growth hormone in prostate cancer cells",
abstract = "Prostate cancer (PCA) growth is mainly driven by androgen receptor (AR), and tumors that initially respond to androgen deprivation therapy (ADT) or AR inhibition usually relapse into a more aggressive, castration-resistant PCA (CRPC) stage. Circulating growth hormone (GH) has a permissive role in PCA development in animal models and in human PCA xenograft growth. As GH and GH receptor (GHR) are both expressed in PCA cells, we assessed whether prostatic GH production is linked to AR activity and whether GH contributes to the castration-resistant phenotype. Using online datasets, we found that GH is highly expressed in human CRPC. We observed increased GH expression in castration-resistant C4-2 compared with castration-sensitive LNCaP cells as well as in enzalutamide (MDV3100)-resistant (MDVR) C4-2B (C4-2B MDVR) cells compared with parental C4-2B.Wedescribe a negative regulation of locally producedGHby androgens/AR in PCA cells following treatment with AR agonists (R1881) and antagonists (enzalutamide, bicalutamide). We also show that GH enhances invasive behavior of CRPC 22Rv1 cells, as reflected by increased migration, invasion, and anchorage-independent growth, as well as expression of matrix metalloproteases. Moreover, GH induces expression of the AR splice variant 7, which correlates with antiandrogen resistance, and also induces insulinlike growth factor 1,which is implicated in PCA progression and ligandindependent AR activation. In contrast, blockade of GH action with the GHR antagonist pegvisomant reverses these effects both in vitro and in vivo. GH induction following ADT or AR inhibition may contribute to CRPC progression by bypassing androgen growth requirements.",
author = "Recouvreux, {M. Victoria} and Wu, {J. Boyang} and Gao, {Allen C} and Svetlana Zonis and Vera Chesnokova and Neil Bhowmick and Chung, {Leland W.} and Shlomo Melmed",
year = "2017",
month = "7",
day = "1",
doi = "10.1210/en.2016-1939",
language = "English (US)",
volume = "158",
pages = "2255--2268",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "7",

}

TY - JOUR

T1 - Androgen receptor regulation of local growth hormone in prostate cancer cells

AU - Recouvreux, M. Victoria

AU - Wu, J. Boyang

AU - Gao, Allen C

AU - Zonis, Svetlana

AU - Chesnokova, Vera

AU - Bhowmick, Neil

AU - Chung, Leland W.

AU - Melmed, Shlomo

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Prostate cancer (PCA) growth is mainly driven by androgen receptor (AR), and tumors that initially respond to androgen deprivation therapy (ADT) or AR inhibition usually relapse into a more aggressive, castration-resistant PCA (CRPC) stage. Circulating growth hormone (GH) has a permissive role in PCA development in animal models and in human PCA xenograft growth. As GH and GH receptor (GHR) are both expressed in PCA cells, we assessed whether prostatic GH production is linked to AR activity and whether GH contributes to the castration-resistant phenotype. Using online datasets, we found that GH is highly expressed in human CRPC. We observed increased GH expression in castration-resistant C4-2 compared with castration-sensitive LNCaP cells as well as in enzalutamide (MDV3100)-resistant (MDVR) C4-2B (C4-2B MDVR) cells compared with parental C4-2B.Wedescribe a negative regulation of locally producedGHby androgens/AR in PCA cells following treatment with AR agonists (R1881) and antagonists (enzalutamide, bicalutamide). We also show that GH enhances invasive behavior of CRPC 22Rv1 cells, as reflected by increased migration, invasion, and anchorage-independent growth, as well as expression of matrix metalloproteases. Moreover, GH induces expression of the AR splice variant 7, which correlates with antiandrogen resistance, and also induces insulinlike growth factor 1,which is implicated in PCA progression and ligandindependent AR activation. In contrast, blockade of GH action with the GHR antagonist pegvisomant reverses these effects both in vitro and in vivo. GH induction following ADT or AR inhibition may contribute to CRPC progression by bypassing androgen growth requirements.

AB - Prostate cancer (PCA) growth is mainly driven by androgen receptor (AR), and tumors that initially respond to androgen deprivation therapy (ADT) or AR inhibition usually relapse into a more aggressive, castration-resistant PCA (CRPC) stage. Circulating growth hormone (GH) has a permissive role in PCA development in animal models and in human PCA xenograft growth. As GH and GH receptor (GHR) are both expressed in PCA cells, we assessed whether prostatic GH production is linked to AR activity and whether GH contributes to the castration-resistant phenotype. Using online datasets, we found that GH is highly expressed in human CRPC. We observed increased GH expression in castration-resistant C4-2 compared with castration-sensitive LNCaP cells as well as in enzalutamide (MDV3100)-resistant (MDVR) C4-2B (C4-2B MDVR) cells compared with parental C4-2B.Wedescribe a negative regulation of locally producedGHby androgens/AR in PCA cells following treatment with AR agonists (R1881) and antagonists (enzalutamide, bicalutamide). We also show that GH enhances invasive behavior of CRPC 22Rv1 cells, as reflected by increased migration, invasion, and anchorage-independent growth, as well as expression of matrix metalloproteases. Moreover, GH induces expression of the AR splice variant 7, which correlates with antiandrogen resistance, and also induces insulinlike growth factor 1,which is implicated in PCA progression and ligandindependent AR activation. In contrast, blockade of GH action with the GHR antagonist pegvisomant reverses these effects both in vitro and in vivo. GH induction following ADT or AR inhibition may contribute to CRPC progression by bypassing androgen growth requirements.

UR - http://www.scopus.com/inward/record.url?scp=85021743749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021743749&partnerID=8YFLogxK

U2 - 10.1210/en.2016-1939

DO - 10.1210/en.2016-1939

M3 - Article

C2 - 28444169

AN - SCOPUS:85021743749

VL - 158

SP - 2255

EP - 2268

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 7

ER -